Non-ischemic cardiomyopathy
Conditions
Interventions
case series:None
Sponsors
The First Affiliated Hospital of Nanjing Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1. 18 years of age 55 mm (men) or >50 mm (women) (UCG assessment) 3. hypertrophic cardiomyopathy: ventricular wall thickness >= 15 mm in any segment or segments of the left ventricular myocardium and exclusion of other diseases causing increased cardiac load; or previous ventricular wall thickness >= 15 mm in any segment or segments of the myocardium and ventricular wall thickness >= 13 mm in any segment or segments of the myocardium at the time of enrollment; LVEF 1 year 5. participants voluntarily participate in the study and have signed an informed consent form
Exclusion criteria
Exclusion criteria: Candidate participants will be excluded from this study if any of the following conditions are met: 1. diabetes mellitus (fasting serum glucose >= 7.0 mmol/L or glycated hemoglobin >= 6.5%) 2. Stenosis >= 50% on coronary arteriography 3. restrictive cardiomyopathy 4. acute myocarditis, uncontrolled tachyarrhythmia atrial fibrillation, and NYHA class IV The following are not recommended Magnetic resonance imaging is not indicated for metallic objects implanted in the body 5. Severe renal insufficiency (estimated glomerular filtration rate 40g/d for women, >80g/d for men, >5 years of alcohol consumption) 7. Pregnant women, those who are breastfeeding or preparing to conceive 8. Patients who do not want to sign the informed consent form 9. Patients who cannot insist on completing the follow-up visit
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Compared enrollment, change in FDG uptake values at 3 months after receiving intensive standard drug therapy based on altered cardiac structure compared to enrollment; | — |
Secondary
| Measure | Time frame |
|---|---|
| change in left ventricular function parameters measured by PET/MR at 3-month follow-up;change in right ventricular function parameters measured by PET/MR at 3-month follow-up;Change in estimated pulmonary artery systolic pressure (PASP) measured by UCG at the 3-month follow-up;Changes in heart rate, the width of QRS waves, and QTc interval measured by ECG at the 3-month follow-up visit;Changes in N-terminal B-type natriuretic peptide (NT-proBNP), high-sensitivity troponin (cTnT), and soluble growth-stimulated expression gene 2 protein (soluble ST2) at the 3-month follow-up;Change in 6-minute walk distance (6MWD) measured by 6-minute walk test (6MWT) at the 3-month follow-up; | — |
Countries
China
Contacts
Public ContactWei Sun
The First Affiliated Hospital of Nanjing Medical University
Outcome results
None listed